Lamb Weston Hldgs 株価情報 (NYSE: LW)

最新ニュース Lamb Weston Hldgs (NYSE:LW) 株価情報

Lamb Weston Hldgs

Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 14% of fiscal 2024 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.

Lamb Weston Holdings Inc

Lifeway Foods Inc

LEWIS & CLARK BANCORP by Lewis & Clark BANCORP

Lewis & Clark Bancorp

LCTI LOW CARBON TECHS INC by LCTI Low Carbon Technologies, Inc.

LCTI Low Carbon Technologies International Inc

LUCKWEL PHARMACEUTICALS by Luckwel Pharmaceuticals Inc.

Lightwave Logic Inc

Longwen Group Corp

SIENNA SR LIVING INC by Sienna Sr Living Inc.

Sienna Senior Living Inc

LEWIS GROUP LTD ORD by Lewis Group Limited, Cape Town

Lewis Group Ltd

LOCAWEB SVS DE IN U/ADR by Locaweb Servicos de Internet S.A

Locaweb Servicos de Internet SA

Lawson Inc

On Thursday, Guardant Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GH#NYSE">GH</a>) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the <a target="_blank" href="http://during the premarket session on last check Thursday." rel="noreferrer noopener">consensus loss of 74 cents</a>.
The cancer diagnostic company reported sales of $201.8 million, up 30% year over year, beating the consensus of $192.14 million, driven by an increase in the volume of clinical tests and biopharma tests, which grew <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43865627/guardant-health-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-2025-outl" rel="noreferrer noopener">24% and 16%, respectively</a>.
The company reported approximately 57,300 oncology clinical tests (excluding Shield) and 11,050 biopharma tests.
The increase in precision oncology revenue was also attributable to an increase in reimbursement for tests due to an increase in Medicare reimbursement for the Guardant360 LDT test to $5,000 and an increase in both Medicare Advantage and commercial payer reimbursement.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43110223/guardant-health-gains-medicare-coverage-for-colorectal-cancer-monitoring-test" rel="noreferrer noopener">Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test</a>
Guidance: Guardant Health forecasts fiscal year 2025 revenue of $850 million—$860 million, versus a consensus of $848.9 million.
Analyst Reaction:
<ul>
<li>William Blair has recently become more optimistic about Guardant. The stock's momentum could continue, especially if investors trust the company's strategy.</li>
<li>While some gains might slow ahead of Exact Sciences Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) midyear results for its blood-based colorectal cancer screening test, analyst Andrew F. Brackmann writes strong financial performance and Guardant's own data updates will support the stock. William Blair maintains <a href="https://www.benzinga.com/quote/GH/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.</li>
<li>Stifel analyst Daniel Arias maintains Guardant Health with a Buy and raises the price target from $45 to $53.</li>
<li>JP Morgan analyst Rachel Vatnsdal reaffirms Guardant Health's Overweight rating and raises the price target from $50 to $55.</li>
<li>Raymond James analyst Andrew Cooper reiterates Guardant Health with an Outperform and raises the price target from $39 to $59.</li>
<li>Goldman Sachs analyst Matthew Sykes maintains Guardant Health with a Buy and raises the price target from $49 to $56.</li>
</ul>
Price Action: GH stock is down 10.60% at $42.40 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43888128/pfizer-discontinues-hemophilia-gene-therapy-beqvez-interest-wanes" target="_blank" rel="noreferrer noopener">Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes</a></li>
</ul>

Analyst Color

Earnings

News

Guidance

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

EXAS

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?

Financial giants have made a conspicuous bullish move on Ford Motor. Our analysis of options history for Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) revealed 9 unusual trades.
Delving into the details, we found 66% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $309,024, and 2 were calls, valued at $81,247.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $7.85 and $11.02 for Ford Motor, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Ford Motor's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Ford Motor's significant trades, within a strike price range of $7.85 to $11.02, over the past month.
<h3>Ford Motor 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740162645_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$0.69</td>
<td>$0.64</td>
<td>$0.64</td>
<td>$7.85</td>
<td>$105.6K</td>
<td>14.5K</td>
<td>0</td>
</tr>
<tr>
<td>F</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.17</td>
<td>$0.16</td>
<td>$0.17</td>
<td>$11.02</td>
<td>$50.8K</td>
<td>46.3K</td>
<td>3.3K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$0.47</td>
<td>$0.45</td>
<td>$0.47</td>
<td>$9.85</td>
<td>$47.0K</td>
<td>22.5K</td>
<td>1.4K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$0.55</td>
<td>$0.54</td>
<td>$0.54</td>
<td>$9.85</td>
<td>$38.9K</td>
<td>52.0K</td>
<td>771</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$2.12</td>
<td>$1.77</td>
<td>$1.86</td>
<td>$10.85</td>
<td>$30.8K</td>
<td>1.7K</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Ford Motor</h3>
Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has nearly 13% market share in the United States, about 10% share in the UK, and under 2% share in China including unconsolidated affiliates. Sales in the US made up about 68% of 2024 total company revenue. Ford has about 171,000 employees, including about 56,500 UAW employees, and is based in Dearborn, Michigan.
<h3>Present Market Standing of Ford Motor</h3>
<ul>
<li>With a trading volume of 28,669,045, the price of F is down by -0.91%, reaching $9.3.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 61 days from now.</li>
</ul>
<h3>Expert Opinions on Ford Motor</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $11.1.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Underweight rating on Ford Motor, which currently sits at a price target of $8. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Ford Motor, targeting a price of $10. 
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Ford Motor, maintaining a target price of $9. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Ford Motor, targeting a price of $15. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Ford Motor with a target price of $13. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Ford Motor options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

A Closer Look at Ford Motor's Options Market Dynamics

William Blair analyst Louie DiPalma downgrades Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) from Outperform to Market Perform.

Downgrades

LDOS

William Blair Downgrades Leidos Holdings to Market Perform

On Friday, Exelixis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) authorized repurchasing up to an additional $500 million of the company&#8217;s common stock before <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43868849/exelixis-announces-a-newly-authorized-500-million-stock-repurchase-program" rel="noreferrer noopener">December 31, 2025</a>.
Exelixis plans to complete the $500 million stock repurchase program, announced in August 2024, in the second quarter of 2025 and commence stock repurchases under the newly authorized stock repurchase program thereafter.
As of the end of fiscal year 2024, Exelixis has returned over $1.2 billion to shareholders through these programs.
Earlier this month, Exelixis reported fourth-quarter adjusted EPS of 55 cents, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 43 cents</a>. The cancer-focused company reported sales of $566.75 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43640071/exelixis-announces-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-corporate-up" rel="noreferrer noopener">consensus of $563.42 million</a>.
Exelixis reaffirmed its 2025 sales guidance of $2.15 billion-$2.25 billion versus consensus of $2.24 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42488323/drug-price-hikes-unsupported-by-evidence-cost-us-815-million-icer-report" rel="noreferrer noopener">Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report</a>
Recently, Exelixis announced the final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx&nbsp;(cabozantinib) in combination with Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo&nbsp;(nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC).
After more than five years of follow-up, the findings demonstrated that the efficacy benefits of Cabometyx&nbsp;in combination with Opdivo were sustained long-term.
At a median follow-up of 67.6 months, Cabometyx, in combination with Opdivo, improved progression-free survival and overall survival compared with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Sutent (sunitinib) in the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43756537/exelixis-announces-final-five-year-follow-up-results-from-checkmate-9er-trial-evaluating-cabometyx" rel="noreferrer noopener">intent-to-treat population</a>.
A subgroup analysis by the International Metastatic RCC Database Consortium (IMDC) risk showed PFS and objective response rates favored Cabometyx in combination with Opdivo versus sunitinib regardless of the IMDC risk group.
In January, Exelixis announced that its supplemental New Drug Application (sNDA) for cabozantinib for adults with previously treated advanced pancreatic neuroendocrine and extra-pancreatic tumors will no longer be discussed at the FDA&#8217;s Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration by the FDA and has a Prescription Drug User Fee Act action <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42896345/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-" rel="noreferrer noopener">date of April 3</a>.
Price Action: EXEL stock is up 3.42% at $36.29 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43888652/trump-medias-strategic-fund-set-to-fuel-mergers-and-acquisitions" target="_blank" rel="noreferrer noopener">Trump Media&#8217;s Strategic Fund Set To Fuel Mergers And Acquisitions: Details</a></li>
</ul>

Biotech

Buybacks

EXEL

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Whales with a lot of money to spend have taken a noticeably bearish stance on Cleanspark.
Looking at options history for Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) we detected 29 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 48% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $359,087 and 22, calls, for a total amount of $987,395.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $4.0 to $37.0 for Cleanspark over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cleanspark's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cleanspark's whale activity within a strike price range from $4.0 to $37.0 in the last 30 days. 
<h3>Cleanspark Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740162639_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.36</td>
<td>$1.32</td>
<td>$1.32</td>
<td>$12.00</td>
<td>$132.0K</td>
<td>6.7K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.35</td>
<td>$1.32</td>
<td>$1.32</td>
<td>$12.00</td>
<td>$98.9K</td>
<td>6.7K</td>
<td>32</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$11.00</td>
<td>$91.2K</td>
<td>89</td>
<td>37</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.72</td>
<td>$0.7</td>
<td>$0.72</td>
<td>$10.00</td>
<td>$72.0K</td>
<td>7.4K</td>
<td>6</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$1.15</td>
<td>$1.11</td>
<td>$1.12</td>
<td>$15.00</td>
<td>$67.5K</td>
<td>21.2K</td>
<td>6.2K</td>
</tr>
</tbody>
</table>

<h3>About Cleanspark</h3>
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
Having examined the options trading patterns of Cleanspark, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Cleanspark</h3>
<ul>
<li>Currently trading with a volume of 13,035,522, the CLSK's price is down by -5.67%, now at $9.49. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
<h3>What Analysts Are Saying About Cleanspark</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $24.666666666666668.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $27. 
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $20. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $27. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cleanspark with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

CLSK

Cleanspark Unusual Options Activity

Financial giants have made a conspicuous bearish move on Freeport-McMoRan. Our analysis of options history for Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) revealed 19 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 57% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $501,366, and 12 were calls, valued at $687,517.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $45.0 for Freeport-McMoRan over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Freeport-McMoRan stands at 4432.4, with a total volume reaching 8,242.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Freeport-McMoRan, situated within the strike price corridor from $30.0 to $45.0, throughout the last 30 days.
<h3>Freeport-McMoRan Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740162633_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.25</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$35.00</td>
<td>$155.0K</td>
<td>833</td>
<td>25</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.45</td>
<td>$7.3</td>
<td>$7.35</td>
<td>$35.00</td>
<td>$147.0K</td>
<td>813</td>
<td>2</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$2.31</td>
<td>$2.3</td>
<td>$2.3</td>
<td>$38.00</td>
<td>$114.7K</td>
<td>1.9K</td>
<td>3.0K</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.47</td>
<td>$1.13</td>
<td>$1.27</td>
<td>$40.00</td>
<td>$99.7K</td>
<td>8.4K</td>
<td>0</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.89</td>
<td>$1.88</td>
<td>$1.88</td>
<td>$39.00</td>
<td>$93.8K</td>
<td>1.5K</td>
<td>564</td>
</tr>
</tbody>
</table>

<h3>About Freeport-McMoRan</h3>
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2024, making it the one of the world's largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. It had about 25 years of copper reserves at end December 2024. we expect it to sell similar amounts of copper midcycle in 2029, though we expect gold volumes to decline to about 700,000 ounces then due to falling production at Grasberg.
In light of the recent options history for Freeport-McMoRan, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Freeport-McMoRan's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 6,060,712, the FCX's price is down by -4.08%, now at $37.37. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 60 days.</li>
</ul>
<h3>Expert Opinions on Freeport-McMoRan</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $45.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on Freeport-McMoRan, which currently sits at a price target of $45. 
&#x2A; An analyst from Jefferies downgraded its action to Hold with a price target of $40. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Freeport-McMoRan, which currently sits at a price target of $50. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Freeport-McMoRan with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Looking At Freeport-McMoRan's Recent Unusual Options Activity

Elon Musk doesn't just work hard—he sleeps hard. The billionaire tech mogul has reportedly been crashing on the floor of his government office, which sits just across from the West Wing of the White House.
Since taking on his new role as head of the Department of Government Efficiency under President Donald Trump, Musk has been spending long hours at the Eisenhower Executive Office Building—so long that he's apparently decided to just sleep there.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
<h2 class="wp-block-heading">Sleeping In The Office—Again</h2>
A Republican source told People that Musk has been &#8220;holed up&#8221; in his government office, sometimes sleeping on the couch and sometimes straight-up on the floor. Not exactly Tesla's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&nbsp; luxury interiors, but Musk has never been big on comfort.
It's not the first time Musk has made an office his bedroom. He famously <a href="https://www.youtube.com/watch?v=fTj3h7wp1Mw">lived in a Tesla factory </a>for three years, sleeping on a couch, under his desk, and even in a tent on the roof. His reasoning back then? Too much work, not enough time to go home.
Now, history seems to be repeating itself—only this time, instead of a Tesla plant, his makeshift bedroom is in a government building next to Trump's White House.
Trending: Many don&#8217;t know there are tax benefits when buying a unit as an investment —<a href="https://www.benzinga.com/money/casa-shares"> Here&#8217;s how to invest in real estate by mirroring BlackRock's big move</a>
<h2 class="wp-block-heading">Government Office? More Like A Full-Time Home</h2>
The EEOB, where Musk has been sleeping, houses various agencies under the Executive Office of the President. It's next to the White House, making it easy for Musk to stay close to Trump.
And while Musk may not have a bed, the EEOB does have perks. A cafeteria, a gym, and even a bowling alley are available for government employees, so at least he's not starving.
But Musk isn't the only one spending extra time in the office. His 4-year-old son, X Æ A-Xii, has reportedly been around "quite a bit." The toddler even made an appearance at a <a href="https://www.youtube.com/watch?v=zqjjPYekxgM&amp;ab_channel=FOX9Minneapolis-St.Paul">Feb. 11 Oval Office press conference,</a> standing beside Musk and Trump while making faces at reporters.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
<h2 class="wp-block-heading">Mar-a-Lago: Musk's Other "Home"</h2>
When Musk isn't sleeping in his government office, he's reportedly spending time at Mar-a-Lago. <a href="https://people.com/elon-musk-sleeping-office-floor-near-white-house-exclusive-11678717">People magazine quoted sources</a> as saying he was living at Trump's Florida resort during the presidential transition, helping shape the administration's tech policies.
One Palm Beach told People last month that Melania Trump was "glad to have a babysitter for Donald" while Musk was hanging around.
<h2 class="wp-block-heading">So, Why Is Musk Sleeping There?</h2>
It's unclear exactly why Musk is choosing to sleep in the EEOB, but given his history, it's likely just about efficiency. If you ask Musk, he'd probably say something like &#8220;too much work, no time to leave.&#8221;
The White House has not commented on his sleeping habits. Neither has Musk. But for now, the world's richest man is apparently sleeping on the floor, just a few steps from Trump's White House.
Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

TSLA

Elon Musk's New Crash Pad? The Floor Of His Government Office Next To Trump's West Wing

Bybit founder Ben Zhou has raised concerns that multisig wallet provider Safe may have been compromised, allowing <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43886224/bybit-founder-confirms-1-4-billion-ethereum-hack-blames-masked-transaction">hackers to steal $1.4 billion</a> in Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). 
Speaking in a live stream, Zhou explained that the attack targeted Bybit's Ethereum cold wallet, but all other wallets, including its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reserves, remain unaffected.
<h3 class="wp-block-heading">How The Attack Unfolded</h3>
Zhou recounted how the attackers manipulated Bybit's signing process while maintaining the appearance of a legitimate Safe transaction.
&#8220;It was a normal URL. I double-checked. It was the Safe URL from the official Safe website. We always use the official website,&#8221; Zhou said.
He explained that as part of standard security measures, he verified the UI and destination address, ensuring it matched Bybit's warm wallet before approving the transfer. 
However, the actual signing message was altered, not to authorize a simple transfer, but instead to modify the smart contract logic of the cold wallet.
&#8220;The hacker changed that transaction into upgrading or changing the Safe smart contract logic so that he gained control over the entire Ethereum cold wallet,&#8221; Zhou revealed.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43883117/coinbase-ceo-brian-armstrong-says-sec-has-agreed-to-end-bogus-enforcement-case-without-penalties">Coinbase CEO Brian Armstrong Says SEC Has Agreed To End &#8216;Bogus&#8217; Enforcement Case Without Penalties</a>
<h3 class="wp-block-heading">Extent of the Damage And Bybit's Response</h3>
The total stolen amount includes:
<ul>
<li>401,347 ETH ($1.12 billion)</li>
<li>90,376 stETH ($253 million)</li>
<li>15,000 cmETH ($44 million)</li>
<li>8,000 mETH ($23 million)</li>
</ul>
Despite the breach, Zhou assured users that withdrawals remain open, although processing times have increased due to a surge in requests. 
At the peak, Bybit was handling nearly 100 times the normal withdrawal volume. 
The exchange is currently relying on a bridge loan from partners to maintain liquidity while resolving the issue.
&#8220;We are not currently buying ETH. We secured almost 80% of the stolen amount as a bridge loan to maintain liquidity,&#8221; Zhou confirmed.
<h3 class="wp-block-heading">Investigating The Breach</h3>
Bybit is working closely with Safe's team to determine whether the attack stemmed from a vulnerability on Safe's end. 
Zhou stated that Safe has paused its services to conduct further internal investigations.
&#8220;It could be that the Safe server was hacked, but we don't know yet. We are actively working with Safe to uncover what happened,&#8221; Zhou said.
<h3 class="wp-block-heading">Tracking The Stolen Funds</h3>
Bybit has also received support from major exchanges such as Binance and MEXC and Gate which have pledged to help track and block the stolen assets. 
Zhou encouraged security firms and blockchain analysts to assist in monitoring the movement of funds in hopes of freezing the stolen Ethereum before it is laundered.
<h3 class="wp-block-heading">What's Next?</h3>
Bybit confirmed that it has the financial reserves to cover client losses, stating that the stolen Ethereum represents only a fraction of the exchange's total assets. 
The company also reiterated its commitment to security enhancements and will continue updating users as the investigation progresses.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43879013/after-im-a-nazi-rant-on-x-kanye-west-is-reportedly-considering-a-token-after-all">After &#8216;I&#8217;m A Nazi&#8217; Rant On X, Kanye West Is Reportedly Considering A Token After All</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Bybit Founder Says $1.4B ETH Hack May Stem From Safe Wallet Compromise

HC Wainwright &amp; Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and maintains $74 price target.

Reiteration

SWTX

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

On Thursday, Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.02</a>.
The automated insulin delivery technology maker reported sales of $597.5 million, up 17.2% year over year (17.1% in constant currency), beating the consensus of $582.81 million, exceeding the guidance range of 12% to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43865349/insulet-reports-full-year-2024-revenue-increase-of-22-and-fourth-quarter-2024-revenue-increase-of-" rel="noreferrer noopener">15% in constant currency</a>.
Total Omnipod revenue reached $585.7 million, an increase of 16.9%, or 16.8%, in constant currency. U.S. Omnipod revenue increased 12.4% to $443.7 million, and International Omnipod revenue rose to $142.0 million, an increase of 33.5%, or 33.1%, in constant currency.
Also Read: <a target="_blank" href="https://www.benzinga.com/etfs/sector-etfs/24/11/41853824/sp-500-breaks-6000-points-dow-soars-above-44000-small-caps-eye-strongest-week-in-4-years-tesla-hits-1-trillion-whats-driving-markets-friday" rel="noreferrer noopener">S&amp;P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday?</a>
Drug Delivery revenue was $11.8 million, an increase of 34.1%. Gross margin expanded 120 basis points to 72.1%.
Operating income of $109.3 million, or 18.3% of revenue, fell 260 basis points, compared with operating income of $106.4 million, or 20.9% of revenue, in the prior year.
The company reported adjusted EBITDA of $151.2 million, or 25.3% of revenue, compared with $137.0 million, or 26.9% of revenue, in the prior year.
"We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 and type 2 patients in the U.S., and we continue to expand in international markets. We generated more than $2 billion in full-year revenue for the first time in Insulet's history, reached more customers, and continued to expand margins&#8230;"
Guidance: For 2025, Insulet expects revenue growth between 16% and 20%. It projects Omnipod sales to increase by 17%-21%. For Q1 2025, Insulet forecasts revenue growth between 22% and 25%, with U.S. Omnipod sales increasing by 21% % to 24%.
William Blair says Insulet's strong fourth-quarter performance confirms its growing momentum in the large, underpenetrated Type 1 and Type 2 diabetes markets.
Analyst Margaret Kaczor Andrew expects this trend to continue in 2025, driven by key growth catalysts that could accelerate adoption and revenue. With shares trading at 8.5 times the midpoint of 2025 sales guidance, William Blair maintains the stock as Outperform.
Price Action: PODD stock is down 2.76% at $280.33 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/02/43884348/nuburu-to-tap-private-equity-funds-for-strategic-acquisitions-in-defense-cybersecurity" target="_blank" rel="noreferrer noopener">Nuburu To Tap Private Equity Funds For Strategic Acquisitions In Defense, Cybersecurity</a></li>
</ul>
Photo via insulet

PODD

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst

William Blair analyst Louie DiPalma downgrades General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) from Outperform to Market Perform.

William Blair Downgrades General Dynamics to Market Perform

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Rajat Gupta downgraded the rating for TrueCar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) from Overweight to Neutral. TrueCar shares closed at $2.67 on Thursday. <a href="https://www.benzinga.com/quote/true/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Madeline Brooks downgraded Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) from Buy to Neutral and lowered the price target from $125 to $100. Akamai shares closed at $98.03 on Thursday. <a href="https://www.benzinga.com/quote/akam/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Mark Fitzgibbon downgraded Amalgamated Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAL#NASDAQ">AMAL</a>) from Overweight to Neutral and lowered the price target from $42 to $38. Amalgamated Financial shares closed at $35.28 on Wednesday. <a href="https://www.benzinga.com/quote/amal/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Benjamin Nolan downgraded Cheniere Energy Partners, L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) from Hold to Sell and raised the price target from $50 to $51. Cheniere Energy Partners shares closed at $63.14 on Thursday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Louie DiPalma downgraded the rating for Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Outperform to Market Perform. Booz Allen Hamilton shares closed at $113.62 on Thursday. <a href="https://www.benzinga.com/quote/BAH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BAH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="621" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179-1024x621.png" alt="" class="wp-image-793643" style="width:536px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179-1024x621.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179-768x465.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43864993/top-3-health-care-stocks-you-may-want-to-dump-in-february">Top 3 Health Care Stocks You May Want To Dump In February</a></li>
</ul>

AKAM

AMAL

TRUE

This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

HC Wainwright &amp; Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Buy and maintains $21 price target.

ORIC

HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target

BofA Securities analyst Christopher Nardone reiterated a <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">Buy rating</a> on the shares of footwear company Crocs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) with a price forecast of $153.
The analyst still believes management can meet its goal of modestly growing Crocs N.A. sales in 2025. Key factors include management's positive outlook on a strong wholesale order book for the next six months, along with the analyst&#8217;s optimistic view of upcoming product innovations, which have already received favorable feedback from wholesale partners.
These innovations include the InMotion clog (currently available at a $60 price point), global and product expansions of popular sandal styles like the Getaway, Miami, and Brooklyn, a greater focus on slippers (primarily in the second half of the year), and continued growth in Jibbitz and collaborations (with a full pipeline for this year).
For N.A. sales growth this year, the analyst anticipates a decline in first-quarter across both channels, followed by a rebound in second-quarter. 
First-quarter will face challenges from the leap year, Easter shifting to second-quarter, and a tougher wholesale comparison, with brick-and-mortar stores showing strong double-digit growth in first-quarter 2024, said the analyst.
International sales will remain the primary driver of overall brand growth for Crocs in 2025 and beyond, the analyst noted.
Also Read: <a href="https://www.benzinga.com/25/02/43880110/james-bond-franchise-shifts-hands-to-amazon-mgm-studios">James Bond&#8217;s New Era: Amazon MGM Studios Takes Creative Reins of Franchise</a>
<h2 class="wp-block-heading">Crocs&#8217; Growth Markets </h2>
According to the analyst, the biggest growth markets for Crocs this year, in terms of dollar value, are expected to be China, India, and Western Europe, including the UK, Germany, and France.
In 2024, India posed a challenge for the company due to regulatory hurdles that hindered supply from meeting demand. However, as 2025 progresses, the company anticipates an improvement in the supply situation. 
With four factories in India, up from three last year, Crocs plans to scale up production and increase output by the end of the year. This expansion will enable quicker distribution of sandals in India, a key move given the strong demand for sandals in the market.
Heydude is still in the early stages of recovery. <a href="https://www.benzinga.com/25/02/43691979/crocs-smashes-q4-earnings-expectations-amid-strong-china-growth-stock-jumps">Fourth-quarter progress</a> was promising, with better-than-expected digital performance and a return to positive DTC growth, the analyst said.
The analyst expects gross margins in 2025 to be similar to last year. But there may be a slight decline, according to official guidance.
Management plans to increase marketing spending to 10% of sales in 2025, up from 9% in 2024. This includes more investment in both brands, with Heydude focusing on brand awareness. 
The analyst is encouraged by the recent partnerships, including Sydney Sweeney, Jelly Roll, and Travis Hunter. Crocs will also boost influencer spending and maintain focus on Tier-1 markets.
HeyDude&#8217;s continued progress will drive multiple growth, the analyst added. Also, the company&#8217;s cash flow potential is undervalued.
Price Action: Crocs shares are trading higher by 0.25% at $109.15 at the last check Friday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a></li>
</ul>
Image: Shutterstock

CROX

Crocs Poised For Expansion, Analyst Counts China, India, Western Europe Among Biggest Growth Markets

At $2,930 on February 21, gold prices have been up 6.6% over the past 30 days and up 45% over the past year. Gold prices have crested the benchmark $3,000 per-ounce level, reaching $3,100 in mid-February.
That performance outpaces stocks, bonds, and most global currencies as volatility has taken hold of financial markets.
And that&#8217;s just the beginning. Wall Street analysts are forecasting even gold will keep rising this year.
Here are the three best ways to play that rise in gold prices.
A case in point &#8211; Goldman Sachs recently called gold prices to rise for the remainder of the year, between $3,100 and $3,300, as central bank demand and political instability push golf prices up by 10%.
&#8220;Policy uncertainty — including tariff fears — stays high; higher speculative positioning for longer could push gold prices as high as $3,300 an ounce by year-end,&#8221; noted Goldman strategist Lina Thomas in a recent research outlook.
Other analysts are in general agreement.
&#8220;A more forceful rally relative to our previous expectation is likely to be driven by deep-rooted bullish sentiment, with gold seen as a safe-haven asset amid a highly uncertain and volatile macro environment,&#8221; UBS said in a new research note.
Commodity sector insiders are even more bullish, with a $4,000 gold price in the cards.
"The current surge in gold prices and demand underscores the profound uncertainty gripping individual investors and global markets,&#8221; said Paul Williams, managing director at Solomon Global, a certified gold and silver bars and coin supplier. "This doesn't look like a short-lived rally —it's a response to entrenched geopolitical tensions, economic fragility, and shifting global power dynamics."
As volatility escalates, gold remains the ultimate hedge, offering stability in an increasingly unpredictable world. "Considering these factors, the $3,000 milestone looks feasible in the next few weeks, and if gold was to make the same gains as it has over the last 12 months, we're looking at $4,250 this time next year," Williams says.
Other gold watchers are pumping the breaks, noting that major global currency movements could tamp commodity prices down in 2025.&nbsp;
"Gold prices will remain elevated throughout 2025 against the backdrop of increased Central Banks purchases, mounting concerns about disruptive US tariffs and demand from newly introduced gold ETFs," said Peter Smith, senior international equity strategist at Federated Hermes, which regularly tracks gold prices. "Central banks are increasingly moving away from Treasuries as investments for their currency reserves, with China in particular, sitting on a $1 trillion trade surplus in 2024, is aggressively buying gold."
However, gold could weaken if the interest rate differential stays wide between the US and the rest of the world. "This could lead to the dollar remaining strong, which should put downward pressure on gold," Smith says. "This is not our base case, but with inflation sticky in the US, the Federal Reserve has signaled it is willing to keep rates higher for longer."
<h2 class="wp-block-heading">Three Gold Plays to Make in 2025</h2>
So, while the trend remains positive for gold and other commodities (silver, for instance, is up 40% so far in 2025), here&#8217;s what sector experts say is the smart play for investors looking to add a yellow hedge to their portfolios.
Gold mining stocks. Stocks of companies that mine gold, such as Newmont (USA), Barrick Gold (Canada), and Freeport McMoRan (USA), offer the opportunity to profit when the metal's price rises, says Julia Khandoshko, CEO of broker Mind Money, a European investment technology and financial engineering hub.
"Investors should note that gold mining stocks can also be risky, so factor that reality into portfolio selection and discuss any trades with a trusted financial advisor," Khandoshko says. "Nevertheless, gold mining stocks can offer better returns than direct investments, especially if the chosen company manages its resources effectively and successfully copes with external challenges."
Gold ETFs. For new investors, spot gold ETFs like SPDR Gold Shares (GLD) can be the easiest and most efficient way to gain exposure to gold, with the larger sector ETFs making the most sense right out of the gate.
Gold ETFs are one of the best options for investing in gold efficiently without the hassle of storing physical bars. "They track the price of gold and are easy to buy and sell, just like a stock," says Chris Heerlein, CEO of REAP Financial, an investment advisory firm based in Austin, Texas.&nbsp;
GLD has some other features gold fund investors might appreciate.
"In addition to being highly liquid, SPDR Gold Shares has always been my favorite gold ETF for two reasons," said Michael Martin, vice president of market strategy at TradingBlock, a Chicago-based market technology trading company. "First, it holds physical gold as opposed to gold futures, so it doesn't suffer decay in value over time. Second, it has the highest assets under management, at $78.1 billion in net assets." The fund is trading at $270 as of February 21.
Physical gold. If you feel ambitious and want direct control over your gold investment, consider investing in physical gold.
"Buying physical gold is a good move because it's the safest and most reliable, as it eliminates counterparty risk," says Alex Ebkarian, COO and co-founder at California-based Allegiance Gold. "It fits the needs of those looking to preserve wealth, diversify their portfolio, and most importantly want and desire to maintain control of the asset and eliminate counterparty risk and addresses declining trust in paper gold."
Buying physical gold requires having "a mid-to-long term outlook on return on investment, as well as preferring ownership of a physical asset versus exposure to the gold stock or fund sector," Ebkarian added.
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0224&amp;utm_campaign=wallstreetadvantage">Cut Through the Market Chaos—Get One Clear Trade Every Morning</a>
Wild swings. Mixed signals. Uncertain trends. Every morning, we deliver one crystal-clear ‘Chart of the Day'—a high-potential setup or a crucial trade to avoid. Get ahead of the market before the next move happens. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0224&amp;utm_campaign=wallstreetadvantage">Get My Chart Now</a>
Image via Shutterstock

Opinion

3 Best Gold Plays for a Volatile 2025

William Blair analyst Louie DiPalma downgrades Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) from Outperform to Market Perform.

William Blair Downgrades Parsons to Market Perform

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Hold to Hold.

ITCI

Needham Reiterates Hold on Intra-Cellular Therapiesto Hold

JP Morgan&nbsp;analyst Rajat Gupta&nbsp;downgraded TrueCar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>)<a target="_blank" href="https://www.benzinga.com/quote/true/analyst-ratings" rel="noreferrer noopener"> from Overweight to Neutral</a>.
This week, the company reported fourth-quarter EPS loss of 7 cents per share, falling short of the analyst consensus estimate of loss of 6 cents&nbsp;and revenue&nbsp;of $46.21 million,&nbsp;missed the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43796921/truecar-releases-fourth-quarter-2024-financial-results-and-stockholder-letter" rel="noreferrer noopener">estimate of $47.29 million</a>.
The analyst cites the weakening tailwinds from inventory and limited visibility on a sustained turnaround in revenue and profits as reasons for the downgrade.&nbsp;
The analyst writes that it was a disappointing quarter for the company with an uncertain path to recovery in growth and profitability, especially as the boost from rising new vehicle inventories begins to fade.&nbsp;
While upcoming products like TCMS, OEM advertising, and data monetization, along with TC+ integration into DMS platforms, offer potential, TRUE must demonstrate clear results from its initiatives and investments in sales and marketing, adds the analyst.
The analyst says that&nbsp;the possibility of a merger or partnership with industry peers cannot be ruled out.&nbsp;
Gupta revised the FY25 EBITDA estimate from the previous +$15 million to breakeven due to weaker dealer revenue. The analyst also lowered the FY26 estimate from +$35 million to +$25 million. 
Due to these significantly reduced projections, the analyst also withdrew his price forecast on the stock.
Price Action: TRUE shares are down 5.21% at $2.531 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43885302" target="_blank" rel="noreferrer noopener">Apple Expands Apple TV+ to Android, Eyes Subscription Growth and Ecosystem Expansion, Analyst Says</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Equities

TrueCar's Outlook Is Cloudy, Analyst Downgrades Stock Seeking More Visibility

HC Wainwright &amp; Co. analyst Mike Colonnese reiterates Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and maintains $350 price target.

COIN

HC Wainwright & Co. Reiterates Buy on Coinbase Global, Maintains $350 Price Target

William Blair analyst Louie DiPalma downgrades CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) from Outperform to Market Perform.

CACI

William Blair Downgrades CACI International to Market Perform

Press Releases

Lamb Weston Holdings Announces Quarterly Dividend

Lamb Weston Reports First Quarter Fiscal 2025 Results; Announces Restructuring Plan and Updates Fiscal Year 2025 Outlook

Lamb Weston Officially Opens New Plant in Kruiningen, Netherlands

Lamb Weston Announces Details of Fiscal Year 2025 Second Quarter Earnings Release

JANA Partners Sends Letter to Board of Directors of Lamb Weston Holdings

Lamb Weston Reports Second Quarter Fiscal 2025 Results; Board Approves $250 Million Share Repurchase Authorization Increase and Increases Quarterly Dividend; Updates Fiscal Year 2025 Outlook

Lamb Weston Announces Appointment of Michael J. Smith as President and Chief Executive Officer

JANA Partners Comments on Lamb Weston Management Change and Financial Results

JANA Partners Sends Letter to Lamb Weston Board of Directors

Lamb Weston Responds to TRC Capital's "Mini-Tender" Offer

Conagra Brands

Cal-Maine Foods

Campbell`s

Flowers Foods

Freshpet

General Mills

Hormel Foods

Hershey

J&J Snack Foods

Kellanova

Kraft Heinz

Lancaster Colony Corporation - Common Stock

Lancaster Colony

Mondelez International, Inc. - Class A Common Stock

Mondelez International

McCormick & Company, Incorporated Common Stock

McCormick & Co

Nomad Foods

Oatly Group AB - American Depositary Shares

Oatly Group

Post Holdings

Pilgrim's Pride Corporation - Common Stock

Pilgrims Pride

Seaboard

Smithfield Foods

JM Smucker

The Simply Good Foods Company - Common Stock

Comments

Lamb Weston Hldgs

ニュース

最新ニュース Lamb Weston Hldgs (NYSE:LW) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル